The RCM market is consolidating rapidly. In February 2026, Clayton, Dubilier & Rice and TowerBrook Capital Partners acquired R1 RCM for $8.9 billion. VERTESS reports that 47 PE deals involving RCM companies closed in 2025. The consolidation wave shows no signs of slowing—and if you own an RCM company generating $15-30MM in revenue, you are receiving acquisition offers.
The question is not whether consolidation will happen. The question is whether you will participate as the seller or the buyer.
Private equity firms see the RCM market consolidation opportunity clearly: acquire smaller companies at 3-6x EBITDA, build platforms with scale and technology infrastructure, exit at 15-20x EBITDA. The arbitrage is substantial, and the execution is systematic.
But here is what most RCM entrepreneurs miss: You can execute the same consolidation playbook using debt financing—maintaining 100% ownership while capturing the entire valuation upside.
Key Takeaways
- The U.S. RCM market reached $172 billion in 2024 and remains highly fragmented despite aggressive consolidation—thousands of independent companies create ongoing opportunity
- Small RCM companies trade at 3-6x EBITDA while platforms with $20MM+ EBITDA command 15-20x multiples—this valuation arbitrage drives the RCM market consolidation wave
- RCM companies can access 3-5x EBITDA in debt financing due to recurring B2B revenue models, strong client retention (95%+ typical), and insulation from reimbursement risk
- Entrepreneur-led rollups using debt financing execute the same strategy as PE-backed platforms—but entrepreneurs maintain control and avoid third-party equity dilution
- 2026 market conditions favor this approach: SOFR down from 5.4% peak, competitive lender environment, and persistent valuation spreads between small companies and scaled platforms
Why Is the RCM Market Consolidating Now?
According to Bainbridge’s 2025 RCM industry report, the revenue cycle management sector presents three characteristics that drive consolidation activity:
Market fragmentation. Despite the $8.9 billion R1 RCM acquisition and 47 PE deals in 2025, the RCM market remains highly fragmented. Thousands of independent RCM companies serve specific specialties, geographies, or provider types. This fragmentation creates consolidation opportunity for both PE platforms and entrepreneur-led acquirers.
Predictable B2B revenue. RCM companies generate recurring revenue from healthcare provider clients, not from patients or payors. This B2B model produces 95%+ client retention rates and cash flow predictability. As we explored in Part 2 of this series, B2B healthcare services companies get significantly better financing terms than physician practices because lenders view recurring revenue models as lower risk.
Valuation arbitrage. The spread between small company valuations and platform valuations creates immediate value capture opportunity. VERTESS data shows RCM transactions follow clear patterns:
| Company Size | EBITDA Multiple | Example Valuation |
|---|---|---|
| Small RCM (<$3MM EBITDA) | 3-6x | $2MM EBITDA = $6-12MM |
| Mid-Size Platform ($5-10MM EBITDA) | 10-12x | $7MM EBITDA = $70-84MM |
| Large Platform ($20MM+ EBITDA) | 15-20x | $22MM EBITDA = $330-440MM |
Private equity firms understand this arbitrage intimately. They acquire smaller companies at 3-6x, integrate them into platforms, and exit at 15-20x when they reach institutional scale. The RCM market consolidation wave is fundamentally driven by this multiple expansion opportunity.
But this arbitrage is not reserved for PE firms. Entrepreneurs with strong RCM companies can execute identical strategies using debt financing.
What Does an Entrepreneur-Led RCM Rollup Look Like?
The rollup strategy is identical whether executed by PE or entrepreneurs. The only difference is capital structure—and who captures the value created.
| The Rollup Playbook | PE-Backed | Entrepreneur-Led |
|---|---|---|
| Platform | PE acquires platform company | Start with YOUR company |
| Capital | PE equity + debt | Debt + seller participation |
| Acquisitions | 5-10 add-ons over 3-5 years | 3-5 add-ons over 2-3 years |
| Integration | Consolidate operations, eliminate redundancies, build scale | Consolidate operations, eliminate redundancies, build scale |
| Exit | 15-20x EBITDA | 15-20x EBITDA (your choice of timing) |
| Value Capture | PE firm captures multiple expansion | YOU capture substantially all of multiple expansion |
Here is the practical math:
Your RCM company: $7.5MM EBITDA, $25MM revenue. PE offers $60MM at 8x EBITDA. You receive immediate liquidity but relinquish future upside.
Entrepreneur rollup alternative: Acquire 3 companies ($2-3MM EBITDA each, $10-15MM purchase prices, 5-6x multiples) over 24-36 months using debt financing, seller rollover equity, and seller notes. Lenders underwrite based on proforma combined EBITDA—creating significantly more debt capacity than standalone numbers suggest (detailed mechanics in next section).
Consolidate platforms, eliminate redundancies, implement synergies. Combined platform reaches $22-25MM EBITDA with stronger margins.
Exit at $24MM EBITDA × 17x multiple = $408MM enterprise value. After debt repayment and seller note settlements, you net significantly more than the $60MM PE offer—while maintaining majority control throughout. Sellers with rollover equity participate in the exit, creating alignment during integration.
As we discussed in Part 1, RCM companies with strong financial profiles can access 3-5x EBITDA in debt financing. This leverage capacity makes entrepreneur-led RCM market consolidation financially viable without PE equity.
How Do RCM Companies Finance Acquisitions Without PE?
The capital structure for entrepreneur-led rollups evolves as you execute multiple acquisitions. Understanding how lenders underwrite based on proforma combined EBITDA is the critical insight most entrepreneurs miss.
How Debt Underwriting Actually Works:
When you acquire a $2.5MM EBITDA company, lenders evaluate the combined entity:
- Your company: $7.5MM EBITDA
- Target company: $2.5MM EBITDA
- Operational synergies: $1.0-1.5MM (eliminating redundant overhead, consolidating technology, improving margins)
- Proforma combined EBITDA: $11-11.5MM
Lenders will provide 3-4x of proforma combined EBITDA in total debt capacity. At 3.5x leverage, that is approximately $38-40MM in available debt.
Capital Structure Progression:
First Acquisition (No Existing Debt):
If you have no debt on your balance sheet, you can finance the entire acquisition with debt alone:
- Purchase price: $12-15MM for a $2.5MM EBITDA company at 5-6x multiple
- Available debt: $38-40MM based on $11MM proforma combined EBITDA at 3.5x
- Structure: 100% debt-financed acquisition
This is the cleanest structure—pure debt, no rollover equity or seller notes needed. You pay the seller 100% cash at closing.
Strategic Alternative for First Acquisition:
Even with full debt capacity available, many entrepreneurs CHOOSE to use rollover equity + seller financing from the start:
- 70% debt ($8.5-10MM)
- 20% rollover equity ($2.5-3MM)
- 10% seller note ($1.2-1.5MM)
Why use this structure even when you don’t need to? Rollover equity creates better seller alignment during the critical 12-24 month integration period. Preserving debt capacity also provides flexibility—if acquisition #2 or #3 takes longer to source, you have not overextended your balance sheet.
Subsequent Acquisitions:
Whether you used 100% debt on your first deal or preserved capacity with rollover equity, the structure for acquisitions #2, #3, and beyond follows the same pattern:
- 60-70% debt (based on growing proforma EBITDA with each acquisition)
- 20% rollover equity
- 10-20% seller note
As you integrate acquisitions and your proforma EBITDA grows from $11MM to $15MM to $18MM+, your available debt capacity expands with each deal. After 2-3 acquisitions, refinance based on the substantially higher EBITDA to pay off seller notes and reset your debt capacity for the next wave.
Rollover Equity Structure:
Offer the seller 20% rollover equity in their company post-close:
- Seller receives 80% cash at closing
- Seller retains 20% ownership stake
- Seller participates in your future exit at 15-20x multiples instead of today’s standalone 5-6x valuation
- Creates powerful incentive alignment during 12-24 month transition period
Why this works: Most small RCM companies have geographic or healthcare segment specialization. Sellers provide critical transition support. With rollover equity, sellers are working to increase the value of their own retained stake—alignment is built into the structure rather than negotiated through earnout terms.
Seller Note:
- 10-20% of purchase price
- Fixed obligation, 3-5 year term, 6-8% interest rate
- Subordinated to senior debt
- Paid off when you refinance based on grown combined EBITDA in years 2-3
If rollover equity does not work: Replace the 20% rollover with earnout structure (performance-based payments over 2-3 years). Earnouts defer payment but create potential disputes over performance measurements and accounting. Rollover equity is cleaner and provides better alignment.
No third-party equity needed: Whether you use 100% debt (first acquisition) or debt + rollover equity + seller note (subsequent acquisitions), you avoid dilution from bringing in outside equity investors. Seller rollover equity keeps sellers aligned during integration while you maintain majority control throughout the rollup process.
Lenders typically require:
- EBITDA margins above 20-25%
- Client retention above 90%
- No single client concentration above 10-15%
- Management team beyond founder alone
- Technology platform capable of integration
- Documented synergy assumptions (lenders will stress-test your proforma EBITDA projections)
The rinse-and-repeat cycle: After 2-3 acquisitions have been integrated and your combined EBITDA has grown from $7.5MM to $15-18MM (with synergies realized across the portfolio), refinance your debt based on the substantially higher EBITDA. Use this refinancing to pay off seller notes from earlier deals and create new debt capacity for additional acquisitions. This cycle allows you to execute 4-6 acquisitions over 24-36 months to reach institutional scale ($20MM+ EBITDA) where exit multiples reach 15-20x.
Should I Sell My RCM Company or Become an Acquirer?
Not every RCM entrepreneur should pursue this strategy. The decision depends on your company’s financial profile, your operational capabilities, and your personal objectives.
You are likely platform-ready if:
Financial strength. Your company generates $5MM+ EBITDA with margins above 25%. You have demonstrated consistent growth and client retention above 95%. These metrics indicate lenders will support acquisition financing.
Operational infrastructure. You have documented processes, technology platforms capable of supporting integration, and management depth beyond yourself. Acquiring companies requires bandwidth—owners who manage all client relationships personally cannot scale through acquisition.
Acquisition visibility. You can identify 3-5 potential acquisition targets in your market. These may be smaller competitors, complementary specialties, or geographic expansion opportunities. Successful rollups require pipeline, not opportunistic deals.
Time horizon. Building through acquisitions typically requires 24-36 months of active involvement. If you need liquidity today, selling makes sense. If you can defer exit for potentially higher returns, debt-financed growth creates optionality.
Entrepreneurial mindset. You are comfortable managing acquisition integration, debt service, and execution risk. Building a platform differs from operating a stable business—it requires growth orientation and risk tolerance.
Comparison of paths:
| Element | Sell to PE Today | Build Then Sell |
|---|---|---|
| Capital Source | PE equity | Debt + seller participation |
| Ownership | PE owns 80-100% | You retain majority control |
| Timeline Pressure | Immediate exit | Flexible (2-5 years) |
| Control | PE board control | Full founder control |
| Upside Capture | PE captures multiple expansion | You capture substantially all expansion |
| Liquidity Timing | Immediate | Deferred |
| Best For | Need liquidity now | Build long-term value |
If you check most platform-ready criteria, the question shifts from “Should I accept the PE offer?” to “Where do I find acquisition targets and how do I structure the financing?”
Why 2026 Market Conditions Favor This Strategy
Three factors align in 2026 to create favorable conditions for entrepreneur-led RCM market consolidation:
Declining cost of debt. SOFR has declined from its 5.4% peak to approximately 3.8% in March 2026—roughly 160 basis points lower. This reduction improves acquisition economics by lowering debt service costs. The same $20MM acquisition facility costs $320,000 less annually at current rates.
Competitive lender environment. Banks, private credit funds, and specialty healthcare lenders compete for quality RCM companies. This competition produces better leverage multiples and more flexible terms for borrowers. Companies with strong financial profiles benefit from multiple financing options.
Persistent valuation arbitrage. Despite aggressive PE consolidation activity, the spread between small company valuations (3-6x) and platform valuations (15-20x) remains wide. This arbitrage creates opportunity for acquirers who can build scale systematically.
Market timing does not guarantee success, but 2026 conditions favor RCM entrepreneurs considering debt-financed growth over immediate sale.
The Bottom Line
The RCM market consolidation wave presents a strategic choice: sell your company today at its current valuation, or use it as the foundation to build a larger platform.
Private equity firms execute rollup strategies because the arbitrage is compelling—acquire at 3-6x, exit at 15-20x, capture the multiple expansion. But this strategy does not require PE equity. RCM companies with strong financial profiles can access debt financing to execute identical playbooks while avoiding third-party equity dilution and maintaining majority control.
This path requires platform readiness—financial strength, operational infrastructure, acquisition pipeline visibility, and 24-36 month time horizon. If your business meets these criteria and you are willing to manage growth complexity, the value creation potential significantly exceeds selling at today’s valuation.
Platforms like CAPX help RCM entrepreneurs structure debt financing for acquisition-driven growth strategies, providing access to multiple lenders who understand healthcare business services and support multi-year rollup plans.
Ready to explore debt financing for your RCM rollup strategy? Schedule a consultation to discuss acquisition financing options.
